Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene by Mittelstrass, Kirstin et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Early onset lung cancer, cigarette smoking and the SNP309 of the 
murine double minute-2 (MDM2) gene
Kirstin Mittelstrass*1, Wiebke Sauter1, Albert Rosenberger2, Thomas Illig1, 
Maria Timofeeva3, Norman Klopp1, Hendrik Dienemann4, Eckart Meese5, 
Gerhard Sybrecht6, Gabi Woelke1, Mathias Cebulla7, Maria Degen8, 
Harald Morr9, Peter Drings4, Andreas Groeschel6, 
Karsten Grosse Kreymborg10, Karl Haeußinger11, Gerd Hoeffken12, 
Christine Schmidt12, Bettina Jilge13, Wilhelm Schmidt13, You-Dschun Ko14, 
Dagmar Taeuscher15, Jenny Chang-Claude3, Heinz-Erich Wichmann1,16, 
Heike Bickeboeller2 and Angela Risch3
Address: 1Helmholtz Center Munich, German Research Center for Environmental Health, Institute of Epidemiology, Munich/Neuherberg, 
Germany, 2Department of Genetic Epidemiology, Georg-August University of Göttingen, Medical School, Göttingen, Germany, 3German Cancer 
Research Centre (DKFZ), Heidelberg, Germany, 4Thoraxklinik Heidelberg GmbH, Heidelberg, Germany, 5Institute of Human Genetics, University 
of the Saarland, Germany, 6Institute of Internal Medicine V, Medical School, University of the Saarland, Germany, 7Municipal Hospital „Sankt 
Georg", Leipzig, Germany, 8Clinic of Pneumology, Waldhof Elgershausen, Greifenstein, Germany, 9Department Internal Medicine-Oncology, 
Thorax-Clinic Heidelberg GmbH, Heidelberg, Germany, 10Centre for Internal Medicine, University Hospital Leipzig, Germany, 11Clinic of 
Pneumology München-Gauting, Munich, Germany, 12Clinic Coswig GmbH, Division Internal Medicine, Coswig, Germany, 13Chemnitz Hospital, 
Clinic for Internal Medicine, Chemnitz, Germany, 14Department of Oncology, University Hospital of Bonn, Germany, 15Wald-Hospital Gera 
GmbH, II. Medical Clinic, Gera, Germany and 16Ludwig-Maximilians-University of Munich, Institute of Medical Data Management, Biometrics 
and Epidemiology, Germany
Email: Kirstin Mittelstrass* - kirstin.mittelstrass@helmholtz-muenchen.de; Wiebke Sauter - wiebke.sauter@helmholtz-muenchen.de; 
Albert Rosenberger - arosenb@gwdg.de; Thomas Illig - illig@helmholtz-muenchen.de; Maria Timofeeva - m.timofeeva@dkfz-heidelberg.de; 
Norman Klopp - klopp@helmholtz-muenchen.de; Hendrik Dienemann - hendrik.dienemann@thoraxklinik-heidelberg.de; 
Eckart Meese - hgemee@med-rz.uni-sb.de; Gerhard Sybrecht - prof.g.w.sybrecht@uniklinikum-saarland.de; Gabi Woelke - woelke@helmholtz-
muenchen.de; Mathias Cebulla - mathias.cebulla@sanktgeorg.de; Maria Degen - maria.degen@t-online.de; 
Harald Morr - harald.morr.waldhof@t-online.de; Peter Drings - peter.drings@thoraxklinik-heidelberg.de; Andreas Groeschel - inagro@med-
rz.uni-sb.de; Karsten Grosse Kreymborg - karsten.g.kreymborg@medizin.uni-leipzig.de; Karl Haeußinger - gauting@asklepios.com; 
Gerd Hoeffken - hoeffken@fachkrankenhasu-coswig.de; Christine Schmidt - schmidt@fachkrnakenhaus-coswig.de; 
Bettina Jilge - b.jilge@skc.de; Wilhelm Schmidt - e.schmidt@skc.de; You-Dschun Ko - y.ko@jk-bonn.de; Dagmar Taeuscher - d.taeuscher@t-
online.de; Jenny Chang-Claude - j.chang-claude@dkfz-heidelberg.de; Heinz-Erich Wichmann - wichmann@helmholtz-muenchen.de; 
Heike Bickeboeller - hbickeb@gwdg.de; Angela Risch - a.risch@dkfz-heidelberg.de
* Corresponding author    
Abstract
The polymorphism SNP309 (rs2279744) in the promoter region of the MDM2 gene has been
shown to alter protein expression and may play a role in the susceptibility to lung cancer. The
MDM2 protein is a key inhibitor of p53 and several mechanisms of MDM2/p53 interactions are
presently known: modulating DNA-repair, cell-cycle control, cell growth and apoptosis.
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We used 635 Caucasian patients diagnosed with lung cancer before 51 years of age and 1300
healthy gender and age frequency matched population Caucasian controls to investigate the
association between the MDM2  SNP309 and the risk of developing early onset lung cancer.
Conditional logistic models were applied to assess the genotype-phenotype association, adjusted
for smoking.
Compared to the GG genotype, the adjusted ORs for the TG and TT genotype were 0.9 (95% CI:
0.7–1.5) and 1.0 (95% CI: 0.7–1.5), respectively. Also no association was found for histological
subtypes of lung cancer. The strength of this study is that within young cases the genetic component
to develop lung cancer may be greater. Our results indicate that the MDM2 SNP309 is not
significantly associated with lung carcinogenesis but point towards gender-specific differences.
Background
Human cells have developed a complex system to protect
themselves from genotoxic damage where the p53 tumor
suppressor gene plays an important role in protecting
against such insults by serving as an integrator of the sig-
nals produced by DNA damage. The MDM2 protein
inhibits p53 transactivation activity and promotes its
export from the nucleus by binding to the transcriptional
activation domain of p53 [1] and acts as an ubiquitin
ligase upon p53 pushing fast degradation of the suppres-
sor [2,3].
Recently, a SNP (SNP309, G2580T) at the intronic p53-
response promoter of MDM2 was identified and associ-
ated with altered Sp1 binding affinity and expression lev-
els of MDM2 RNA and protein [4]. Contradictory results
were reported regarding the MDM2 SNP309 association
with lung cancer [5-8]. In addition the polymorphism was
correlated with a decreased age at the time of lung cancer
diagnosis in Li-Fraumeni syndrome and sporadic sarcoma
patients [4]. Our study is the first report on a large German
case-control study of young lung cancer patients (age of
onset < 51 years) investigating the MDM2 SNP 309.
Methods
Study population
The study population consists of 635 lung cancer patients
with an onset of disease ≤ 50 years of age and 1300
healthy population controls, all Caucasians. Controls
were recruited from the KORA S3 + S4 (Cooperative
Health Research in the Augsburg Region) surveys, which
are large population-based consecutive cross-sectional
studies [9,10] and matched by gender and 3-years age
groups to cases in a 1:2 matching design. In order to
increase the sample size of early onset lung cancer patients
we included cases from two existing studies. 472 cases
were from the LUCY (LUng Cancer in the Young) study.
Additional 163 cases were derived from the hospital-
based Heidelberg Lung Cancer (HLC) study from the Tho-
raxklinik Heidelberg [11].
The LUCY-study is a multicenter study with 31 participat-
ing clinics all over Germany. Only newly diagnosed
patients with histological or cytological confirmed pri-
mary lung cancer entered the study. Detailed epidemio-
logic data on family history, tobacco and smoking
exposure, education and occupational exposure have
been collected and blood samples were taken.
The HLC-study is an ongoing hospital based case-control
study. The DKFZ has recruited over 1000 LC cases at and
in collaboration with the Thoraxklinik Heidelberg. 163 of
these LC cases with onset of disease under age 51,
recruited between 01/1997 and 12/2003 were included in
the analysis. Data on occupational exposure, tobacco
smoking and educational status were assessed by a self-
administered questionnaire.
The KORA-study is a population based epidemiological
survey of persons living in or near the city of Augsburg,
Southern Germany conducted since 1984. No major pop-
ulation stratification between KORA (Southwest Ger-
many) and two other cohorts from Northern Germany
could be detected in an intensive study using a genomic
control approach [12].
Informed consent was obtained from all study partici-
pants and the studies were approved by the ethical com-
mittee of the Bayerische Landesärztekammer, the
corresponding local ethics committees of the participating
clinics and the ethical committee of the University of Hei-
delberg.
Genotyping
The detection of the MDM2  gene polymorphism
(rs2279744; G > T; NM_002392.2) was based upon anal-
ysis of primer extension products generated from previ-
ously amplified genomic DNA using a chip-based MALDI-
TOF (matrix-assisted laser desorption/ionization time-of
flight) mass spectrometry platform (SEQUENOM, Inc.,
San Diego, CA) as described in Weidinger et al. (2004)
[13]. Genotyping was performed by laboratory personnel
blinded to case-control status. Standard genotyping qual-BMC Cancer 2008, 8:113 http://www.biomedcentral.com/1471-2407/8/113
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ity control included 10% duplicate samples, negative and
positive samples and checking for Hardy-Weinberg equi-
librium (HWE).
Statistical analysis
Hardy Weinberg Equilibrium (HWE) was tested using a
log-likelihood test. Conditional logistic regression models
were applied to test for a genotype-phenotype association
and gene-smoking interaction, with conditioning on the
matched variables age groups (≤ 40 years, 41–45 years,
46–50 years) and gender. The amount of smoking expo-
sure (s. table 1 for definition) was considered as a covari-
ate to adjust for a smoking-related increase in lung cancer
risk. The overall level of significance was set to 5%. We
investigated differences between multiple characteristics
(age of onset, gender, LC subtype and MDM2 SNP390
genotype) of both cases-samples by calculating a propen-
sity score, which is defined as the conditional probability
of assignment to a particular case-sample given a vector of
observed covariates [14]. We then calculated kappa as
measurement of agreement between true and the assigned
Table 1: Characteristics of lung cancer cases and healthy controls
Category Group Cases (n = 635) Controls
LUCY-study
(n = 472)
HLC-study
(n = 163)
KORA-study
(n = 1300)
gender men 66% (310) 59% (96) 63% (819)
women 34% (162) 41% (67) 37% (481)
age at diagnosis (mean ± SD) men 45.4 ± 4.1 45.4 ± 3.7 45.2 ± 4.3
women 44.5 ± 4.6 45.1 ± 4.6 44.7 ± 4.7
age at diagnosis (men) ≤ 40 years 13% (40) 11% (11) 14% (116)
41–45 years 32% (99) 33% (32) 31% (251)
46–50 years 55% (171) 55% (53) 55% (451)
age at diagnosis (women) ≤ 40 years 17% (28) 16% (11) 17% (83)
41–45 years 31% (51) 25% (17) 30% (144)
46–50 years 51% (83) 58% (39) 53% (255)
LC subtypes (men) NSCLC-Adenocarcinoma 26% (81) 35% (34)
other NSCLC 40% (125) 43% (41)
SCLC 26% (81) 20% (19)
other types 7% (22) 2% (2)
LC subtypes (women) NSCLC-Adenocarcinoma 44% (71) 54% (36)
other NSCLC 22% (36) 24% (16)
SCLC 25% (41) 16% (11)
other types 9% (14) 6% (4)
smoking exposure (packyears) minimally exposed (0–10) 12% (57) 13% (21) 54% (712)
lightly exposed (11–20) 17% (81) 8% (13) 14% (178)
moderately exposed (21–30) 31% (144) 20% (33) 15% (188)
highly exposed (31++) 39% (186) 52% (85) 15% (192)
unknown 0.9% (4) 7% (11) 2% (30)
MDM2 SNP309 genotypes* TT 42% (199) 44% (71) 42% (547)
TG 47% (222) 44% (71) 46% (598)
GG 10% (49) 13% (21) 12% (149)
unknown 0.3% (2) -- 0.5% (6)
mean age at diagnosis (95% CI) TT 45.1 (44.5–45.7) 44.8 (43.7–45.8)
TG 45.3 (44.7–45.8) 45.6 (44.7–46.5)
GG 44.6 (43.3–45.9) 45.9 (44.2–47.6)
LUCY-study: Lung Cancer in the Young study; HLC-Study: Heidelberg lung cancer study; Other NSCLC = other non small cell lung cancers 
(NSCLC excluding adenocarcinoma), SCLC = small cell lung cancer, other types = other kinds of lung cancerBMC Cancer 2008, 8:113 http://www.biomedcentral.com/1471-2407/8/113
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membership to a case-sample and performed a McNe-
mar's test for agreement between these.
All analyses were performed with SAS 9.1®. Power analy-
ses for the single marker association was done according
to the method of Slager 2001 [15] and for the single
marker interaction tests it was accomplished by using
Nquery Advisor 4.0.
Results
Population characteristics
There was no statistically significant difference in the dis-
tribution of gender (p = 0.13) and age (p = 0.80) between
patients and controls. The distribution of the histology
subtypes within the cases can be seen in table 1. Although
one might see a higher percentage of NSCLC-Adenocarci-
noma within HCL-cases, the difference between both
case-populations was by far not significant (p = 0.617). In
total, there are no major differences between both case-
populations. Applying the propensity score approach we
found no agreement between the true and the assigned
membership to a case-sample (kappa 0.01; 95% CI: -0.1
to 0.1). Thus we have no evidence to assume group differ-
ences shown by the multiple characteristics considered (p
= 1.00).
Genotyping
The genotyping success rates were above 99.5%. No dis-
cordance between the duplicates was found.
Associations of the MDM2 SNP309 with lung cancer
No deviations from HWE were found in the genotype dis-
tribution of the MDM2 polymorphism among controls (p
= 0.453) or cases (p = 0.474). All but eight samples were
successfully genotyped for the MDM2 SNP309. The minor
allele frequency (MAF) was 0.34 (CI: 0.35–0.33). Lung
cancer was not found to be associated with the MDM2
SNP309 (p = 0.988). Compared to the GG genotype, the
smoking adjusted ORs for the TG and TT genotypes were
1.0 (95% CI: 0.7–1.5) and 1.0 (95% CI: 0.7–1.5), respec-
tively. Both case populations compared separately to the
controls showed no significant associations (Table 2).
Gender related subgroup analysis yielded no association
of the MDM2 SNP309 and lung cancer (Table 2, 3, 4).
Also no influence in lung cancer risk by the MDM2
SNP309 was observed for the diverse histological sub-
types of lung cancer (Table 3, 4, 5).
Furthermore it was investigated whether an interaction
existed between the MDM2 SNP309 and the smoking sta-
tus. We did not find an association between the MDM2
SNP309 and lung cancer for any of the defined smoking
exposure level groups (Table 3, 5).
Even though no significant difference between both case-
populations could be stated statistically, we observed
twice as many female GG-carriers among HLC-cases
(21%) than in the control- or LUCY population (10%)
(Table 5). We also observed an enrichment of NSCLC-
and NSCLC adenocarcinoma-cases in the HLC-sample
(78%) compared to the LUCY-sample (66%). Lind et al.
(2006) [6] recently reported a gender specific risk dispos-
ing effect of the T-allele of MDM2 SNP309 for NSCLC
cases. We therefore additionally performed a subgroup
analysis restricted to NSCLC-cases and tested for gender
differences. Compared to the GG genotype, the smoking
adjusted ORs for the TG and TT genotypes for female
NSCLC-cases were 0.8 (95% CI: 0.4–1.6) and 0.71 (95%
CI: 0.4–4.0), respectively. For men the ORs were 1.2 (95%
CI: 0.7–2.8) and 1.2 (95% CI: 0.7–2.9), respectively
(Table 4). Although a possible NSCLC risk modification
of MDM2 SNP309 seems to be reverse between men and
women, we failed to achieve significance for this gender
difference (p = 0.237). We also tested a gender specific
genetic association within both case-samples separately.
Neither within all HLC-cases (p = 0.083) nor within all
Table 2: Association of MDM2 SNP309 with lung cancer within 
both case-populations
genotype OR 95% CI p-value
LUCY cases (n = 470) vs. KORA controls (n = 815)
TG vs. GG 1.1§ 0.7–1.6 0.794
TT vs. GG 1.0§ 0.7–1.6 0.841
men: LUCY cases (n = 309) vs. KORA controls (n = 815)
TG vs. GG 1.1§§ 0.7–1.8 0.706
TT vs. GG 1.1§§ 0.7–1.8 0.751
women: LUCY cases (n = 161) vs. KORA controls (n = 815)
TG vs. GG 1.0§§ 0.5–2.1 0.937
TT vs. GG 1.0§§ 0.5–2.1 0.966
gender difference in genotypic ORs 0.778
HLC cases (n = 163) vs. KORA controls (n = 479)
TG vs. GG 0.9§ 0.5–1.7 0.761
TT vs. GG 1.0§ 0.5–1.7 0.906
men: HLC cases (n = 96) vs. KORA controls (n = 479)
TG vs. GG 1.2§§ 0.5–3.0 0.648
TT vs. GG 1.6§§ 0.7–3.7 0.314
women: HLC cases (n = 67) vs. KORA controls (n = 479)
TG vs. GG 0.7§§ 0.3–1.6 0.372
TT vs. GG 0.5§§ 0.2–1.3 0.159
gender difference in genotypic ORs 0.083
HLC cases vs. LUCY cases (distribution of TT/TG/GG)
all $0.773
men $0.383
women $0.100
§ conditional to age/gender-strata (6 groups) and adjusted for smoking 
exposure§§ conditional to age-strata (3 groups) and adjusted for 
smoking exposure and gender$. Fishers Exact TestBMC Cancer 2008, 8:113 http://www.biomedcentral.com/1471-2407/8/113
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LUCY-cases (p = 0.778) were significant gender differ-
ences found (Table 2).
MDM2 SNP309 was recently reported to be associated
with an earlier onset of disease [4]. The average age at the
time of diagnosis in our cases overall was not significantly
different (p = 0.923) between the variant genotypes (Table
1) and can be assumed as homogeneous between both
case-samples (p = 0.7157). The mean age of diagnosis of
men was 45.2 (median = 46.0 years, range 26.0 – 50.0
years) and of women 44.7 years (median = 46.0 years,
range 24.0 – 50.0 years). Women, however, with the
MDM2  SNP309 were diagnosed at a younger age (8
months) compared to males, but this was not statistically
significant (p = 0.059, 95% CI: 0 to 16 months). Within
the LUCY-case population this gender difference was 10
months (95% CI: 0.3 to 20 months, p = 0.044), and only
6 months (95% CI: -10 to 22 months, p = 0.496) in the
much smaller HLC-case population.
Discussion
Reports have shown an increased risk of lung cancer for
the G allele of the MDM2 SNP309 in Korean and Chinese
populations [7,16,17]. In contrast, in our study of 635
Caucasian lung cancer patients with age of onset < 51
years and 1300 controls the MDM2 SNP309 was not asso-
ciated with lung cancer. We did not observe a significant
overall association either with the G allele or with the T
allele as reported by Li et al. (2006) where they showed an
increased lung cancer risk with the T/T genotype in a non-
Hispanic white population [18]. We had a 90% power
(alpha = 0.05, two sided test) to detect a minimum overall
OR of 1.4 for the MDM2 SNP309 T allele. Thus our study
had sufficient power to detect an OR of 1.6 (95% CI: 1.1–
2.5) and 1.8 (95% CI: 1.5–2.3) reported in other studies
[6,7]. The estimated allele frequency (T: 0.66, G: 0.34)
agrees well with further reported allele frequencies in Cau-
casian populations [6,8]. Differences between the two
case populations were statistically not palpable (Table 1,
Table 3: Association of MDM2 SNP309 with lung cancer
gender Genotype OR 95% CI p-value
men* TG vs. GG 1.1 0.7 – 2.0 0.630
men* TT vs. GG 1.2 0.7 – 2.2 0.504
women* TG vs. GG 0.9 0.5 – 1.6 0.723
women* TT vs. GG 0.8 0.5 – 1.3 0.565
histology
NSCLC-Adenocarcinoma** TG vs. GG 1.0 0.6 – 1.7 0.991
NSCLC-Adenocarcinoma** TT vs. GG 1.0 0.6 – 1.8 0.890
other NSCLC** TG vs. GG 1.0 0.6 – 1.8 0.873
other NSCLC** TT vs. GG 0.9 0.5 – 1.6 0.751
SCLC** TG vs. GG 1.0 0.5 – 1.9 0.980
SCLC** TT vs. GG 1.2 0.6 – 2.1 0.637
smoking exposure (packyears)
lightly exposed (11–20 PY)*** TT vs. GG 1.0 0.6 – 1.8 0.928
lightly exposed (11–20 PY)*** TG vs. GG 1.0 0.5 – 1.7 0.857
moderately exposed (21–30 PY)*** TT vs. GG 1.0 0.6 – 1.7 0.960
moderately exposed (21–30 PY)*** TG vs. GG 0.9 0.6 – 1.6 0.822
highly exposed (31++ PY)*** TT vs. GG 0.9 0.5 – 1.4 0.595
highly exposed (31++ PY)*** TG vs. GG 0.8 0.5 – 1.3 0.369
*conditional to age-strata (3 groups: ≤ 40 years, 41–45 years, 46–50 years), adjusted for smoking exposure; **conditional to age/gender-strata (6 
groups) and adjusted for smoking exposure; ***conditional to age/gender-strata (6 groups)
Table 4: Association of MDM2 SNP309 with lung cancer within 
NSCLC cases
genotype OR 95% CI p-value
all: NSCLC cases (n = 434) vs. controls (n = 1295)
TG vs. GG 1.1§ 0.7–1.6 0.828
TT vs. GG 1.0§ 0.7–1.5 0.841
men: NSCLC cases (n = 280) vs. controls (n = 815)
TG vs. GG 1.2§§ 0.7–2.9 0.422
TT vs. GG 1.2§§ 0.7–2.9 0.515
women: NSCLC cases (n = 154) vs. controls (n = 479)
TG vs. GG 0.8§§ 0.4–1.6 0.471
TT vs. GG 0.7§§ 0.4–4.0 0.323
gender difference in genotypic ORs 0.237
§ conditional to age/gender-strata (6 groups) and adjusted for smoking 
exposure§§ conditional to age-strata (3 groups) and adjusted for 
smoking exposure and genderBMC Cancer 2008, 8:113 http://www.biomedcentral.com/1471-2407/8/113
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Table 5: MDM2 SNP309 genotypes
Group MDM2 SNP309 genotypes Cases (n = 635) Controls
LUCY-study
(n = 472)
HLC-study
(n = 163)
KORA-study
(n = 1300)
gender men TT 128 (41%) 47 (49%) 350 (43%)
TG 148 (48%) 42 (44%) 366 (45%)
GG 33 (11%) 7 (7%) 99 (12%)
unknown 1 (0%) 3 (0%)
women TT 71 (44%) 24 (36%) 197 (41%)
TG 74 (46%) 29 (43%) 232 (48%)
GG 16 (10%) 14 (21%) 50 (10%)
unknown 1 (0%) 3 (0%)
age at diagnosis ≤ 40 years TT 30 (44%) 11 (50%) 85 (43%)
TG 30 (44%) 8 (36%) 91 (46%)
GG 6 (9%) 3 (14%) 21 (11%)
unknown 2 (3%) 2 (1%)
41–45 years TT 58 (39%) 21 (43%) 172 (44%)
TG 73 (49%) 23 (47%) 185 (47%)
GG 19 (13%) 5 (10%) 37 (9%)
unknown 1 (0%)
46–50 years TT 111 (44%) 39 (42%) 290 (41%)
TG 119 (47%) 40 (43%) 322 (46%)
GG 24 (9%) 13 (14%) 91 (13%)
unknown 3 (0%)
smoking exposure level (SEL) minimally exposed TT 28 (49%) 7 (33%) 297 (42%)
(0–10 PY) TG 19 (33%) 12 (57%) 332 (47%)
GG 9 (16%) 2 (10%) 81 (11%)
unknown 1 (2%) 2 (0%)
lightly exposed (> 10–20 PY) TT 29 (36%) 7 (54%) 72 (40%)
TG 42 (52%) 5 (38%) 81 (46%)
GG 9 (11%) 1 (8%) 24 (13%)
unknown 1 (1%) 1 (1%)
moderately exposed (> 20–30 PY) TT 65 (45%) 13 (39%) 81 (44%)
TG 70 (49%) 15 (45%) 86 (46%)
GG 9 (6%) 5 (15%) 19 (10%)
unknown
highly exposed TT 76 (41%) 41 (48%) 84 (44%)
(> 30++ PY) TG 89 (48%) 33 (39%) 87 (45%)
GG 21 (11%) 11 (13%) 21 (11%)
unknown
LC subtypes NSCLC- Adenocarcinoma TT 63 (41%) 35 (50%)
TG 75 (49%) 23 (33%)
GG 13 (9%) 12 (17%)
unknown 1 (1%)
other NSCLC TT 68 (43%) 17 (30%)
TG 73 (46%) 34 (60%)
GG 19 (12%) 6 (11%)
SCLC TT 55 (45%) 15 (50%)
TG 55 (45%) 12 (40%)
GG 13 (11%) 3 (10%)
other types TT 13 (27%) 4 (40%)
TG 19 (39%) 2 (20%)
GG 4 (8%)
unknown 13 (27%) 4 (40%)BMC Cancer 2008, 8:113 http://www.biomedcentral.com/1471-2407/8/113
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2, 3, 4, 5) but the HLC-sample was enriched with NSCLC-
cases. According to Steffens et al. 2006 [12] we can assume
the German population to be nearly free of population
stratification, which may lead to false positive or false neg-
ative association findings in genetic case control studies.
Differences in ethnicity between our population and
those reported by Zhang et al. 2006 [7], Park et al. 2006
[16] and Jun et al. 2007 [19] may provide a partial expla-
nation for the lack of association in our study. On the
other hand Hu et al. 2006 [5] also did not observe an asso-
ciation between the MDM2 SNP309 and lung cancer in a
Chinese population. Our results were similar to the report
of Pine et al. (2006) [8]. They also did not find any overall
association between the MDM2 SNP309 and lung cancer
in a Caucasian (USA) population. Similarly, we did not
observe an interaction between the MDM2 SNP309 and
smoking. A combined analysis of the available genotype
data of the MDM2 SNP309 showed an increased risk of
lung cancer for the GG versus the TT genotype (OR: 1.3,
95% CI: 1.1–1.4) [20]. A main difference between the two
study populations is the age of cases. Therefore one possi-
ble explanation would be, that the MDM2 variant is only
associated with risk of later onset lung cancer. On the
other hand a large study of 1787 Caucasian lung cancer
patients could also not confirm the results of this meta-
analysis. They did not find any significant association of
the MDM2 SNP309 and lung cancer [21]. The popula-
tions used in the meta-analysis are mostly of Asian origin
so possibly pointing to population heterogeneity.
Lind et al. (2006) [6] recently reported a gender specific
risk disposing effect of the T allele of MDM2 SNP309 for
NSCLC cases. They investigated NSCLC-cases and found
female carriers of the GG-genotype associated to LC by an
OR of 4.1, while male homozygotes showed a non signif-
icant OR of 1.3. Our data slightly tends to confirm this
finding, but the corresponding OR for NSCLC women is
just 1.4 (1/0.71 of Table 4), which is much smaller and
not significant (p = 0.323). In our study none of the gen-
der specific ORs nor a test of gender differences yielded
significance. But we noticed discrepancies of such a gen-
der specific genetic association between the two case-sam-
ples of our investigation. A gender difference was almost
significant (p = 0.08) for the much smaller single center
case-sample of the HLC-study. There, the OR for female
carriers of the GG-Genotype (corresponding to Lind et al.
(2006)) was 1.9 (1/0.54 of Table 4) and for male carriers
0.6 (1/1.56 of Table 4). With n = 67 female and n = 96
male cases these subsamples are quite small and the tests
for association are underpowered. Thus our investigation
provides no significance for such gender specific associa-
tions by itself. Comparing our study samples to that of
Lind et al. (2006) the major difference is the age of onset
of LC. The presented investigation focused on early onset
LC cases which are in the mean 20 years younger than
those of Lind et al. (2006). As the population by Lind et
al. (2006) is of Norwegian origin there might also be dif-
ferent gene-environmental interactions.
MDM2 SNP309 was reported by Bond et al. 2004 [4] to be
associated with an earlier onset of disease for Li-Fraumeni
syndrome and sporadic sarcoma patients. We did not
observe a lower age of diagnosis in our study, similar find-
ings are also described by Hu et al. 2006 [5] and Pine et al.
2006 [8]. Our sample size is large enough to detect a shift
of two years for the time of diagnosis with 90% power
(alpha = 0.05) for heterozygous as well as for
homozygous allele carriers. Recently Bond et al. 2006 [22]
reviewed the possible interaction between the SNP309
and the oestrogen receptor status in women. Within
women of the LUCY case population we could observe an
earlier onset of disease of 10 months (95% CI: 0.3 to 20
months, p = 0.044), but only 6 months (95% CI: -10 to 22
months, p = 0.496) in the by far smaller HLC-case popu-
lation. Recent data suggest that the promoter polymor-
phism in the MDM2 gene may influence the age of cancer
onset in a gender specific way [23-25].
Conclusion
Given that lung cancer is a result of gene-environmental
interaction, the genetic component may be a particularly
strong risk factor among early onset lung cancer patients.
In our sample, after controlling for gender and other char-
acteristics, the overall data suggest that the MDM2
SNP309 might not be a sufficient risk factor of lung car-
cinogenesis not even in young cases where the genetic
component might have a larger contribution to the risk of
disease. It might modify the time of tumour onset, espe-
cially in women, supporting the model, that female-spe-
cific hormones, such as oestrogen, could allow the
SNP309 to accelerate tumour formation. Our investiga-
tion provides no significance for gender specific associa-
tions by itself; it points only towards gender specific
differences. Therefore further studies have to be con-
ducted to explicitly study these gender-specific effects.
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